rentradВестник рентгенологии и радиологииJournal of radiology and nuclear medicine0042-46762619-0478Limited Liability Company "LUCHEVAYA DIAGNOSTIKA", Russian Association of Radiologists10.20862/0042-4676-2024-105-3-170-180rentrad-880Research ArticleКЛИНИЧЕСКИЕ СЛУЧАИCASE REPORTSРезультаты применения различных методов реперфузии головного мозга у пациентов с острым ишемическим инсультомResults of Using Different Brain Reperfusion Methods in Patients with Acute Ischemic Strokehttps://orcid.org/0009-0002-2036-6344ХадисоваА. Г.KhadisovaA. G.

Хадисова Амина Гаджиевна, аспирант кафедры лучевой диагностики

ул. Кирочная, 41, Санкт-Петербург, 191015

Amina G. Khadisova, Postgraduate, Chair of Radiation Diagnostics

ul. Kirochnaya, 41, Saint Petersburg, 191015

https://orcid.org/0000-0001-8253-2382ЗахматоваТ. В.ZakhmatovaT. V.

Захматова Татьяна Владимировна, д. м. н., доцент кафедры лучевой диагностики; доцент кафедры лучевой диагностики и медицинской визуализации c клиникой

ул. Кирочная, 41, Санкт-Петербург, 191015

ул. Аккуратова, 2, Санкт-Петербург, 197349

Tatiana V. Zakhmatova, Dr. Med. Sc., Associate Professor, Chair of Radiation Diagnostics; Associate Professor, Chair of Radiation Diagnostics and Medical Imaging with a Clinic

ul. Kirochnaya, 41, Saint Petersburg, 191015

ul. Akkuratova, 2, Saint Petersburg, 197349

tvzakh@mail.ruhttps://orcid.org/0000-0003-2949-6268СергееваТ. В.SergeevaT. V.

Сергеева Татьяна Васильевна, к. м. н., доцент кафедры медицинской реабилитации и спортивной медицины; ассистент кафедры нейрохирургии и неврологии

ул. Литовская, 2Е, Санкт-Петербург, 194100

Университетская наб., 7-9, Санкт-Петербург, 199034

Tatyana V. Sergeeva, Cand. Med. Sc., Associate Professor, Chair of Medical Rehabilitation and Sports Medicine; Assistant Professor, Chair of Neurosurgery and Neurology

ul. Litovskaya, 2Е, Saint Petersburg, 194100

Universitetskaya naberezhnaya, 7-9, Saint Petersburg, 199034

ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава РоссииРоссияMechnikov North-Western State Medical UniversityRussian FederationФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России; ФГБУ «Национальный медицинский исследовательский центр им. В.А. Алмазова» Минздрава РоссииРоссияMechnikov North-Western State Medical University; Almazov National Medical Research CentreRussian FederationФГБОУ ВО «Санкт-Петербургский государственный педиатрический медицинский университет» Минздрава России; ФГБОУ ВО «Санкт-Петербургский государственный университет»РоссияSaint Petersburg State Pediatric Medical University; Saint Petersburg State UniversityRussian Federation2024091020241053170180Copyright © Хадисова А.Г., Захматова Т.В., Сергеева Т.В., 20242024Хадисова А.Г., Захматова Т.В., Сергеева Т.В.Khadisova A.G., Zakhmatova T.V., Sergeeva T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.russianradiology.ru/jour/article/view/880

Острый ишемический инсульт (ОИИ) занимает одно из ведущих мест в структуре инвалидности и смертности взрослого населения во всем мире, что обусловливает значительное социальное и экономическое бремя данной патологии. Последние достижения в диагностике и лечении ОИИ позволили существенно снизить летальность и улучшить функциональные исходы у пациентов. Однако сохраняются категории больных с неудовлетворительными результатами и осложнениями реперфузионной терапии, летальность в которых может превышать общий показатель. До настоящего времени остаются спорными аспекты определения показаний и выбора предпочтительного метода лечения церебральной реперфузии. В представленных клинических наблюдениях рассмотрены результаты применения тромболитической терапии и тромбоэкстракции у пациентов разных возрастных групп при ОИИ. Отмечено большое значение различных методов нейровизуализации (мультисрезовой компьютерной томографии, компьютерной ангиографии, ультразвукового дуплексного сканирования экстракраниальных и интракраниальных артерий) для своевременного установления диагноза и определения оптимальной тактики реваскуляризации.

Acute ischemic stroke (AIS) occupies one of the leading places in the structure of disability and mortality in adult population throughout the world, which causes a significant social and economic burden of this pathology. Recent advances in AIS diagnosis and treatment have significantly reduced mortality and improved functional outcomes in patients. However, categories of patients with unsatisfactory results and complications of reperfusion therapy still remain. In some of them, mortality may exceed the overall rate. To this day, there are controversial aspects in determining indications and choosing the preferred method of cerebral reperfusion. The presented cases describe the results of using thrombolytic therapy and thromboextraction in AIS patients of different age groups. The importance of various neuroimaging methods (multislice computed tomography, computed angiography, duplex ultrasound of extra- and intracranial arteries) for timely diagnosis and determination of optimal revascularization tactics was noted.

острый ишемический инсультОИИтромболитическая терапиятромбоэкстракциямультисрезовая компьютерная томографияМСКТкомпьютерная ангиографиядуплексное сканированиеacute ischemic strokeAISthrombolytic therapythromboextractionmultislice computed tomographyMSCTcomputed angiographyduplex ultrasoundReferencesШамалов Н.А., Стаховская Л.В., Клочихина О.А. и др. Анализ динамики основных типов инсульта и патогенетических вариантов ишемического инсульта. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019; 119(3): 5–10. https://doi.org/10.17116/jnevro20191190325.Shamalov NA, Stakhovskaya LV, Klochikhina OA, et al. An analysis of the dynamics of the main types of stroke and pathogenetic variants of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2019; 119(3): 5–10 (in Russ). https://doi.org/10.17116/jnevro20191190325.The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333(24): 1581–7. https://doi.org/10.1056/NEJM199512143332401.The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333(24): 1581–7. https://doi.org/10.1056/NEJM199512143332401.Hacke W, Kaste M, Fieschi C, еt al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995; 274(13): 1017–25.Hacke W, Kaste M, Fieschi C, еt al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995; 274(13): 1017–25.Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998; 352(9136): 1245–51. https://doi.org/10.1016/s0140-6736(98)08020-9.Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998; 352(9136): 1245–51. https://doi.org/10.1016/s0140-6736(98)08020-9.Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999; 282(21): 2019–26. https://doi.org/10.1001/jama.282.21.2019.Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999; 282(21): 2019–26. https://doi.org/10.1001/jama.282.21.2019.Sandercock P, Wardlaw JM, Lindley RI, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012; 379(9834): 2352–63. https://doi.org/10.1016/S0140-6736(12)60768-5.Sandercock P, Wardlaw JM, Lindley RI, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012; 379(9834): 2352–63. https://doi.org/10.1016/S0140-6736(12)60768-5.Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008; 359(13): 1317–29. https://doi.org/10.1056/NEJMoa0804656.Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008; 359(13): 1317–29. https://doi.org/10.1056/NEJMoa0804656.Mateen FJ, Buchan AM, Hill MD. Outcomes of thrombolysis for acute ischemic stroke in octogenarians versus non agenarians. Stroke. 2010; 41(8): 1833–5. https://doi.org/10.1161/STROKEAHA.110.586438.Mateen FJ, Buchan AM, Hill MD. Outcomes of thrombolysis for acute ischemic stroke in octogenarians versus non agenarians. Stroke. 2010; 41(8): 1833–5. https://doi.org/10.1161/STROKEAHA.110.586438.Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019: 50(12): e344–418. https://doi.org/10.1161/STR.0000000000000211.Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019: 50(12): e344–418. https://doi.org/10.1161/STR.0000000000000211.Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2012; 375(9727): 1695–703. https://doi.org/10.1016/S0140-6736(10)60491-6.Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2012; 375(9727): 1695–703. https://doi.org/10.1016/S0140-6736(10)60491-6.Saver JL, Levine SR. Alteplase for ischaemic stroke-much sooner is much better. Lancet. 2010; 375(9727): 1667–8. https://doi.org/10.1016/S0140-6736(10)60634-4.Saver JL, Levine SR. Alteplase for ischaemic stroke-much sooner is much better. Lancet. 2010; 375(9727): 1667–8. https://doi.org/10.1016/S0140-6736(10)60634-4.Hasan TF, Hasan H, Kelley RE. Overview of acute ischemic stroke evaluation and management. Biomedicines. 2021; 9(10): 1486. https://doi.org/10.3390/biomedicines9101486.Hasan TF, Hasan H, Kelley RE. Overview of acute ischemic stroke evaluation and management. Biomedicines. 2021; 9(10): 1486. https://doi.org/10.3390/biomedicines9101486.Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2012; 363(9411): 768–74. https://doi.org/10.1016/S0140-6736(04)15692-4.Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2012; 363(9411): 768–74. https://doi.org/10.1016/S0140-6736(04)15692-4.Broderick JP, Palesch YY, Demchuk AM, et al. Endovascular therapy after Intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013; 368(10): 893–903. https://doi.org/10.1056/NEJMoa1214300.Broderick JP, Palesch YY, Demchuk AM, et al. Endovascular therapy after Intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013; 368(10): 893–903. https://doi.org/10.1056/NEJMoa1214300.Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015; 372(11): 1019–30. https://doi.org/10.1056/NEJMoa1414905.Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015; 372(11): 1019–30. https://doi.org/10.1056/NEJMoa1414905.Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016; 387(10029): 1723–31. https://doi.org/10.1016/S0140-6736(16)00163-X.Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016; 387(10029): 1723–31. https://doi.org/10.1016/S0140-6736(16)00163-X.Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018; 378(1): 11–21. https://doi.org/10.1056/NEJMoa1706442.Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018; 378(1): 11–21. https://doi.org/10.1056/NEJMoa1706442.

The authors declare that there are no conflicts of interest present.